At its 2026 Annual Meeting held on June 9, 2026, Organon & Co. stockholders approved an amendment and restatement of the 2021 Incentive Stock Plan, which increases the number of common shares available for issuance by 8,000,000. Shareholders also elected ten directors to serve until the 2027 annual meeting, approved executive compensation on a non-binding advisory basis, and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the 2026 fiscal year. The meeting saw approximately 77% of outstanding shares represented. Organon & Co. is a pharmaceutical company.
